About a decade ago, triggered by unexplained growth and variability in cardiovascular testing, 1 eff orts to redefi ne imaging quality led to an appreciation of the importance of selecting the right test for the right patient (ie, giving rise to appropriate use criteria) and measuring the eff ect of testing on outcomes, in addition to measures such as image acquisition and interpretation. 2 Although appropriate use criteria are now an established part of evidence-based cardiovascular care, imaging outcomes have not been defi ned in a more meaningful way, partly because of the many steps needed to translate test data into knowledge (ie, diagnostic thinking), action (ie, treatments), and ultimately outcomes.
Nevertheless, there have been strong calls to explore the downstream consequences of imaging as a necessary step in more fully understanding its risks and benefi ts, which would then help to establish scenarios in which imaging does, and does not, add value. 3 This task has been made more diffi cult in the era following the COURAGE 4 and FAME 5 trials, in which the diagnosis of anatomical coronary artery disease has been uncoupled from a need for revascularisation, and in the post-CONFIRM era, 6 in which non-obstructive coronary artery disease is recognised to be a powerful predictor of future events.
A few trials have been done to rise to this challenge in the primary prevention area and in the triage of acute chest pain, variously using risk factor burden, clinical events, and effi ciency as endpoints. Randomised trial data assessing the eff ect of testing in the very large stable chest pain population have been scarce, but are now present in the form of two new large studiesthe Computed Tomography Coronary Angiography in Patients with Suspected Angina due to Coronary Heart Disease: the Scottish Computed Tomography of the HEART (SCOT-HEART) trial 7 reported by David Newby and colleagues in The Lancet, and the PROspective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial. 8 In SCOT-HEART, 4146 patients completing an assessment for stable chest pain were randomly assigned to CT coronary angiography (CTCA) in addition to usual care or to usual care alone, which generally included an exercise treadmill test. The trial's primary endpoint, certainty of the attribution of symptoms to angina due to presence of coronary artery disease, showed an increase in the CTCA group (relative risk 1·79, 95% CI 1·62-1·96), as did the closely related secondary endpoint of certainty of diagnosis of coronary artery disease (2·56, 2·33-2·79). Additional secondary endpoints included diagnostic reclassifi cation and changes in diagnostic and therapeutic approaches, which all happened more frequently in the CTCA group. Although investigators recorded no diff erences in the frequency or stability of angina, rates of revascularisation, or admittance to hospital, there was a non-signifi cant reduction in the rate of death or myocardial infarction in the CTCA group. This latter fi nding is intriguing but should be treated with caution: it was one of 22 prespecifi ed secondary endpoints, and the absolute diff erence between the two groups was only 16 events.
Because randomised trials of cardiovascular imaging are fairly new, much can be learned from the well-done SCOT-HEART study to guide clinical care and future research. Many crucial questions are raised: fi rst, in the absence of a feasible placebo strategy, how can imaging studies prevent or control bias in favour of the intervention? In SCOT-HEART, CTCA created greater diagnostic certainty in CT readers than in non-reader clinicians. Second, should imaging fi ndings be prospectively linked to mandated care algorithms? Incomplete abortion is defi ned as the presence of retained products of conception with no well-defi ned gestation sac. It is a potentially life-threatening condition that without well-timed and proper treatment can lead to severe complications such as haemorrhagic shock, sepsis, and death. Abortionrelated complications still contribute substantially to maternal morbidity and mortality in sub-Saharan Africa.
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Backup treatment of complications from unsafe abortion and spontaneous abortion (postabortion care) is an eff ective intervention to reduce maternal mortality. The post-abortion care model consists of emergency treatment of abortionrelated complications, post-abortion contraceptive counselling, and free contraception. 2 The lack of physicians in many low-income countries restricts women's access to post-abortion care. In Africa, the shortage of trained health-care providers is greatest in rural and remote areas where maternal mortality and morbidity is highest. 3 In The Lancet, Marie KlingbergAllvin and colleagues 4 report the results of a multicentre equivalence randomised controlled trial to examine
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Because a test can only aff ect outcomes by changing care, the failure to follow best practices, or the ineff ectiveness of treatments, can be falsely attributed to the test. Indeed in the PARR-2 trial, 9 although performance of a cardiac PET viability scan did not change outcomes in patients with heart failure overall, patients who received PET-guided care (and not just a scan) had fewer events. SCOT-HEART bypassed this issue by using the upstream outcome of diagnostic certainty, but clinical events remain the preferred evidentiary standard.
Third, if intermediate outcomes are used, what outcomes are most important to both patients and clinicians in guiding test selection? Diagnostic thinking is important, and might change processes of care, as shown in SCOT-HEART, but other unexamined parameters such as effi ciency, safety, and avoidance of unnecessary invasive procedures might be equally, if not more, salient. Finally, although the very low rate of clinical events in SCOT-HEART (ie, cardiovascular death or myocardial infarction were reported in just 68 [1·6%] participants in 1·7 years of follow-up) is encouraging in documenting an excellent prognosis for patients with new-onset stable chest pain receiving contemporary care, to show a diff erence in patient outcomes with diff erent testing strategies in view of this excellent prognosis would need a large incremental test eff ect driving diff erences in downstream care, an extremely large study sample, prolonged follow-up, or a combination of these factors.
SCOT-HEART 7 provides important data regarding the eff ect of the addition of a new technology to usual care, and explores new methods for the theory and practice of imaging outcomes research. However, more work is needed in this new specialty before the value of cardiovascular imaging can be fully understood.
